The observation group in this study showed a significant decrease in VEGF levels after treatment compared to the control group (P<0.05), indicating that the combination of Xindilimumab, albumin bound paclitaxel, and cisplatin in the treatment of stage IB - III B NSCLC can reduce VEGF levels and inhibit tumor cell proliferation. This evidence concerns the gene ALB and non-small cell lung carcinoma.